clinical trial · NCT03809624
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
Metastatic Solid TumorsNon-small Cell Lung CancerMelanomaHead and Neck Squamous Cell CarcinomaGastric AdenocarcinomaRenal Cell CarcinomaEsophageal AdenocarcinomaNasopharyngeal CarcinomaINBRX-105 - PDL1x41BB antibodyPembrolizumab
brief summary
This is a first-in-human, open-label, nonrandomized, four-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX-105 and INBRX-105 in combination with Pembrolizumab. INBRX-105, a next generation bispecific antibody, targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor. INBRX-105 provides localized conditional T-cell co-stimulation through 4-1BB agonism.
started
Jan 30, 2019
primary completion
Oct 3, 2024
completion
Oct 3, 2024
last updated
Oct 23, 2024
official title
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 / 2 Study of INBRX-105 and INBRX-105 in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol